Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 186

Results For "C"

9160 News Found

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr
News | January 28, 2025

Torrent Pharmaceuticals posts Q3 FY25 consolidated PAT at Rs. 503 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2,842 crores during the period ended December 31, 2024


RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr
News | January 28, 2025

RPG Life Sciences posts Q3 FY25 PAT higher at Rs. 34.93 Cr

RPG Life Sciences has reported total income of Rs. 176.02 crore during the period ended December 31, 2024


Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr
News | January 28, 2025

Laurus Labs posts Q3 FY25 consolidated PAT higher at Rs. 92.30 Cr

Laurus Labs has reported total income of Rs. 1,424.47 crores during the period ended December 31, 2024


Mankind Pharma launches 45-day healthcare mission at Mahakumbh
Healthcare | January 28, 2025

Mankind Pharma launches 45-day healthcare mission at Mahakumbh

The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring


Toray develops membrane doubling filtration for biopharmaceutical manufacturing processes
News | January 28, 2025

Toray develops membrane doubling filtration for biopharmaceutical manufacturing processes

The company will initially supply prototypes to diverse customers to evaluate in purification processes for producing gene therapy drugs with a view to swift commercialization


Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr
News | January 27, 2025

Granules India Q3 FY25 PAT drops 6% to Rs 118 Cr

The company said it voluntarily paused production at the Gagillapur plant in September 2024 for risk assessment on account of the USFDA observations


Pfizer’s BRAFTOVI combination demonstrates improved response for mutant metastatic colorectal cancer
News | January 27, 2025

Pfizer’s BRAFTOVI combination demonstrates improved response for mutant metastatic colorectal cancer

BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation


SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development
News | January 27, 2025

SaponiQx, Probius, and Ginkgo Bioworks to revolutionize vaccine adjuvant development

Groundbreaking collaboration harnesses AI-driven insights and advanced manufacturing to create next-generation adjuvants for emerging biological threats


AstraZeneca plans US$ 570 million investment in Canada
News | January 27, 2025

AstraZeneca plans US$ 570 million investment in Canada

700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies


Cupid gets female condom variant UNFPA prequalified to supply 100% of upcoming South Africa tender
News | January 25, 2025

Cupid gets female condom variant UNFPA prequalified to supply 100% of upcoming South Africa tender

Earlier, Cupid Limited had been eligible to supply 75% of the contract for female condoms in previous tenders